DPPIV inhibition: promising therapy for the treatment of type 2 diabetes.
Wiedeman
Paul E
PE
Abbott Laboratories, Department R4CP, Building AP9B, 100 Abbott Park Road, Abbott Park, IL 60064-6113, USA.
D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000201:enzymology; D018819:Dipeptidyl Peptidase 4; D054873:Dipeptidyl-Peptidase IV Inhibitors; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D013329:Structure-Activity Relationship
D054873:Dipeptidyl-Peptidase IV Inhibitors; D004791:Enzyme Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4